Loss per Share

The following table sets forth the computation of basic and diluted loss per share for the three and six months ended June 30, 2015 and 2014:



	Three Months Ended June 30,						Six Months Ended June 30,
	2015			2014			2015			2014
	(in thousands, except per share amounts)
Basic and diluted
Net loss attributable to The Medicines Company	$	(46,592	)	$	(5,157	)	$	(41,558	)	$	(10,153	)

Weighted average common shares outstanding, basic	65,903			64,400			65,541			64,277
Plus: net effect of dilutive stock options, restricted common shares and shares issuable upon conversion of convertible senior notes due 2017	—			—			—			—
Weighted average common shares outstanding, diluted	65,903			64,400			65,541			64,277

Loss per share attributable to The Medicines Company, basic	$	(0.71	)	$	(0.08	)	$	(0.63	)	$	(0.16	)
Loss per share attributable to The Medicines Company, diluted	$	(0.71	)	$	(0.08	)	$	(0.63	)	$	(0.16	)

Basic loss per share is computed using the weighted average number of shares of common stock outstanding during the period, reduced where applicable for outstanding yet unvested shares of restricted common stock. The number of dilutive common stock equivalents was calculated using the treasury stock method. For the three months ended June 30, 2015 and 2014, options to purchase 1,243,124 shares and 1,426,987 shares, respectively, of common stock that could potentially dilute basic loss per share in the future were excluded from the calculation of diluted earnings per share as their effect would have been anti-dilutive. For the six months ended June 30, 2015 and 2014, options to purchase 1,313,494 shares and 1,777,605 shares, respectively, of common stock that could potentially dilute basic loss per share in the future were excluded from the calculation of diluted earnings per share as their effect would have been anti-dilutive.

For the three and six months ended June 30, 2015, there were 220,021 and 267,399 shares, respectively, of unvested restricted stock excluded from the calculation of diluted loss per common share as their effect would be anti-dilutive. For the three and six months ended June 30, 2014, there were 233,761 and 303,829 shares, respectively, of unvested restricted stock excluded from the calculation of diluted loss per common share.

In January 2015, the Company issued, at par value, $400.0 million aggregate principal amount of 2.5% convertible senior notes due 2022 (the 2022 Notes) (see note 10, Convertible Senior Notes). The conversion rate for the 2022 Notes was initially, and remains 29.8806 shares of the Company’s common stock per $1,000 principal amount of the 2022 Notes, which is equivalent to an initial conversion price of approximately $33.47 per share of the Company’s common stock. For the three and six months ended June 30, 2015, there was no dilutive effect of the 2022 Notes as the stock price did not exceed the conversion price and the Company reported a loss.

In June 2012, the Company issued, at par value, $275.0 million aggregate principal amount of 1.375% convertible senior notes due June 1, 2017 (the 2017 Notes) (see note 10, Convertible Senior Notes). In connection with the issuance of the 2017 Notes, the Company entered into convertible note hedge transactions with respect to its common stock (the 2017 Note Hedges) with several of the initial purchasers of the 2017 Notes, their affiliates and other financial institutions (the 2017 Hedge Counterparties). The options that are part of the 2017 Note Hedges are not considered for purposes of calculating the total shares outstanding under the basic and diluted net income per share, as their effect would be anti-dilutive. The 2017 Note Hedges are expected generally to reduce the potential dilution with respect to shares of the Company's common stock upon any conversion of the Notes in the event that the market price per share of the Company's common stock, as measured under the terms of the 2017 Note Hedges, is greater than the strike price of the 2017 Note Hedges, which initially corresponded to the conversion price of the 2017 Notes and is subject to anti-dilution adjustments substantially similar to those applicable to the conversion rate of the 2017 Notes. The number of shares of common stock issuable upon conversion of the 2017 Notes excluded from the calculation of diluted loss per share for the three months ended June 30, 2015 was zero. For the six months ended June 30, 2015, the number of shares issuable upon conversion of the 2017 Notes excluded from the diluted loss per share calculation was 27,870 as their effect would be anti-dilutive.

In addition, in connection with the 2017 Note Hedges, the Company entered into warrant transactions with the 2017 Hedge Counterparties, pursuant to which the Company sold warrants (the 2017 Warrants) to the Hedge Counterparties to purchase, subject to customary anti-dilution adjustments, up to 9.8 million shares of the Company's common stock at a strike price of $34.20 per share. For the three and six months ended June 30, 2015 and June 30, 2014, the 2017 Warrants did not have a dilutive effect on loss per share because the average market price during the periods presented was below the strike price and the Company reported a loss for all periods. The 2017 Warrants will have a dilutive effect with respect to the Company's common stock to the extent that the market price per share of the Company's common stock, as measured under the terms of the 2017 Warrants, exceeds the applicable strike price of the 2017 Warrants. However, subject to certain conditions, the Company may elect to settle all of the 2017 Warrants in cash.